## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

	OMB APPRO	APPROVAL									
	OMB Number:	3235-0287									
ı	Estimated average burden										
ı	hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

maddion (b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person*  Walsh Deina H						2. Issuer Name and Ticker or Trading Symbol Bone Biologics Corp [ BBLG ]									ck all applic Directo Officer	or (give title		10% Owner Other (specify		
(Last) (First) (Middle) C/O BONE BIOLOGICS CORP, 2 BURLINGTON WOODS DR. SUITE 100					3. Date of Earliest Transaction (Month/Day/Year) 01/15/2025										X Officer (give title below)  Chief Financial Officer					
(Street) BURLINGTON, MA 01803 (City) (State) (Zip)					4. If Amendment, Date of Original Filed (Month/Day/Year)									Line	Individual or Joint/Group Filing (Check Applicable le)  X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tal	ole I - Nor	n-Deriv	ative	e Se	ecuritie	s A	cquired, l	Disp	osed	of, or B	enef	icially	y Owned					
1. Title of Security (Instr. 3)  2. Trans Date (Month)					ar)	2A. Deemed Execution Date if any (Month/Day/Ye		Code (In	tion Dispos		curities Acquired (A) seed Of (D) (Instr. 3, 4			5. Amou Securitie Benefici Owned F Reported	es ally Following	Form: [	n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
													Code	Price	Transact (Instr. 3	ion(s)				
Common	Stock										1,	,875		D						
			Table II -						quired, Di s, option						Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security  3. Transaction Date (Month/Day/Year)  (Month/Day/Year)  3. Transaction Execution D if any (Month/Day/			Date, T	Code (In				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amour of Securities Underlying Derivat Security (Instr. 3 a 4)		vative	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Natur of Indired Beneficia Ownersh (Instr. 4)	
					ode V		(A)	(D)	Date Exercisable	Expiration Date		Title	Amo or Num Shai	ber of						
Employee Stock Option	\$0.9678	01/15/2025			A		27,055		01/15/2025 01/15/20		15/2027	Common Stock			\$0	27,055		D		
Employee	\$3.61								(2)	01/	17/2026	Common	12	500		12,500		D		

## **Explanation of Responses:**

\$57.6

Employee

Stock Option

1. This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.

(2)

2. This option is fully vested as of the date of this report.

/s/ Deina Walsh

78

Common

01/25/2025

01/17/2025

78

D

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.